Forte Biosciences, Inc. (FBRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 7M 14M 21M Q4 '17: 41K Q1 '18: 39K Q2 '18: 38K Q3 '18: 18M Q4 '18: 18M Q1 '19: 18M Q2 '19: 18M Q3 '19: 36K Q4 '19: 36K Q4 '17 Q2 '18 Q4 '18 Q2 '19 Q4 '19

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-105M -70M -35M 0 35M 70M 105M Q4 '16: -31.7M Q1 '17: -32.7M Q2 '17: -33.7M Q3 '17: -34.9M Q4 '17: -37.6M Q1 '18: -41.9M Q2 '18: -48.6M Q3 '18: -37.4M Q4 '18: -45.9M Q1 '19: -49.9M Q2 '19: -35.2M Q3 '19: -37.3M Q4 '20: -46.3M Q1 '21: -49M Q2 '21: -20M Q3 '21: -22.7M Q4 '21: -21.5M Q1 '22: -19.3M Q2 '22: -16.5M Q3 '22: -12.3M Q4 '22: -13.9M Q1 '23: -18.2M Q2 '23: -24.3M Q3 '23: -31M Q4 '23: -32.5M Q1 '24: -33.4M Q2 '24: -37.2M Q3 '24: -35.6M Q4 '24: -36.6M Q1 '25: -44.9M Q2 '25: -43.7M Q3 '25: -53.4M Q4 '25: -70.7M Q1 '26: -77M Q2 '26: -90M Q4 '17 Q1 '19 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-90M -60M -30M 0 30M 60M 90M Q4 '16: -33.5M Q1 '17: -34.5M Q2 '17: -35.6M Q3 '17: -36.5M Q4 '17: -38.9M Q1 '18: -42.7M Q2 '18: -49.8M Q3 '18: -40.2M Q4 '18: -49M Q1 '19: -37.3M Q2 '19: -21.8M Q3 '19: -22.1M Q4 '19: -13.1M Q1 '20: -14M Q2 '20: -48.1M Q3 '20: -52.5M Q4 '20: -46.5M Q1 '21: -49.2M Q2 '21: -20.3M Q3 '21: -22.9M Q4 '21: -21.7M Q1 '22: -19.5M Q2 '22: -16.7M Q3 '22: -12.3M Q4 '22: -13.9M Q1 '23: -18.1M Q2 '23: -23.9M Q3 '23: -30.5M Q4 '23: -31.5M Q1 '24: -32.1M Q2 '24: -35.8M Q3 '24: -34.2M Q4 '24: -35.5M Q1 '25: -43.7M Q2 '25: -42.5M Q3 '25: -51.7M Q4 '25: -69.4M Q1 '26: -75.9M Q2 '26: -87.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q4 '16: -29.5M Q1 '17: -31M Q2 '17: -30.6M Q3 '17: -29.7M Q4 '17: -31.1M Q1 '18: -36.3M Q2 '18: -39.7M Q3 '18: -31.7M Q4 '18: -34.5M Q1 '19: -39.4M Q2 '19: -12.6M Q3 '19: -14.1M Q4 '19: -2.8M Q1 '20: 12M Q2 '20: -8.1M Q3 '20: -15.3M Q4 '20: -18.4M Q1 '21: -19.6M Q2 '21: -19.5M Q3 '21: -16.9M Q4 '21: -16.7M Q1 '22: -14.6M Q2 '22: -12.1M Q3 '22: -8.9M Q4 '22: -8.2M Q1 '23: -11.4M Q2 '23: -15.5M Q3 '23: -22.6M Q4 '23: -28.7M Q1 '24: -30.2M Q2 '24: -30.6M Q3 '24: -29.7M Q4 '24: -30.7M Q1 '25: -34.4M Q2 '25: -38.6M Q3 '25: -44.4M Q4 '25: -50.9M Q1 '26: -59.3M Q2 '26: -72M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q4 '16: -30.1M Q1 '17: -31.6M Q2 '17: -31.1M Q3 '17: -30.1M Q4 '17: -31.8M Q1 '18: -37.1M Q2 '18: -41.1M Q3 '18: -33.5M Q4 '18: -36.4M Q1 '19: -41.3M Q2 '19: -13.9M Q3 '19: -14.6M Q4 '19: -2.9M Q3 '24: -29.7M Q4 '24: -30.8M Q1 '25: -34.5M Q2 '25: -38.6M Q3 '25: -44.6M Q4 '25: -51M Q1 '26: -59.4M Q2 '26: -72M Q2 '17 Q1 '18 Q4 '18 Q3 '19 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 8M 16M 24M Q2 '21: 13.6M Q3 '21: 14.2M Q1 '22: 14.8M Q2 '22: 14.8M Q3 '22: 18.9M Q1 '23: 21M Q2 '23: 21M Q2 '21 Q3 '21 Q1 '22 Q2 '22 Q3 '22 Q1 '23 Q2 '23

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-750.00 -500.00 -250.00 0.00 250.00 500.00 750.00 Q4 '16: -15.22 Q1 '17: -15.69 Q2 '17: -12.59 Q3 '17: -9.00 Q4 '17: -5.72 Q1 '18: -2.26 Q2 '18: -2.51 Q3 '18: -2.03 Q4 '18: -2.44 Q1 '19: -2.53 Q2 '19: -301.72 Q3 '19: -631.70 Q4 '19: -631.19 Q1 '20: -631.42 Q2 '20: -340.94 Q3 '20: -11.39 Q4 '21: -1.54 Q1 '22: -1.35 Q2 '22: -1.13 Q3 '22: -0.77 Q4 '22: -0.80 Q1 '23: -0.95 Q2 '23: -1.16 Q3 '23: -7.55 Q4 '23: -8.26 Q1 '24: -11.97 Q2 '24: -18.33 Q3 '24: -16.30 Q4 '24: -12.17 Q1 '25: -9.51 Q2 '25: -3.69 Q3 '25: -0.14 Q4 '25: -4.77 Q1 '26: -4.64 Q2 '26: -4.65 Q4 '17 Q1 '19 Q2 '20 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.